Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Epanova in Chinese Healthy Subjects
NCT03574142Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, sponsored by AstraZeneca. Primary endpoints: Plasma concentrations versus time profile of EPA and DHA at Day 20, Observed maximum plasma concentration at Day 17 and 4 more. Started Jun 2018; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03574142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574142.